Japan · Delayed Price · Currency is JPY Sumitomo Chemical Company Earnings Call Transcripts
Fiscal Year 2026
-
FY 2025 saw strong recovery with core operating income up JPY 68 billion and net income up JPY 22.4 billion year-over-year. FY 2026 guidance projects further growth, led by Agro & Life Solutions and ICT & Mobility Solutions, with continued portfolio shift and strategic investments in growth areas.
-
Core operating income and net income rose sharply year-on-year, driven by pharma and divestiture gains, despite lower sales revenue. FY2025 guidance was raised, with a higher dividend payout and improved outlook for semiconductors, while non-recurring losses are expected in Q4.
-
Core operating income and net profit rose sharply year-over-year, led by pharma segment gains and favorable forex, despite lower overall sales revenue. Full-year guidance was raised for core profit, with strong North American pharma sales and improved margins in key materials segments expected to drive results.
-
First quarter FY2025 saw improved core operating income and segment profitability, despite lower sales revenue and a net loss driven by foreign exchange impacts. Outlook for the first half remains positive, with strong shipments and one-time gains expected to support results.
Fiscal Year 2025
-
Management is prioritizing core businesses in organic synthesis, crop protection, and advanced materials, while expanding into regenerative medicine and cell therapy. Financial targets include improved capital efficiency and shareholder returns, with ongoing structural reforms and a focus on innovation to stay competitive.
-
Core operating income rebounded sharply in FY 2024, driven by improved segment performance and asset sales, with net income and free cash flow turning positive. FY 2025 guidance anticipates higher profits despite lower revenue, amid FX and tariff headwinds.
-
The new business plan targets a V-shaped recovery and sustainable growth by focusing investments and R&D on Agro and ICT, while advancing structural reforms and capital efficiency. Financial targets include JPY 200 billion core operating income by FY 2027 and JPY 350 billion by 2035, with strengthened governance and digital transformation initiatives.
-
Q3 FY2024 saw a strong turnaround with core operating income and net income both sharply higher year-on-year, driven by Pharma and ICT & Mobility. Full-year guidance is unchanged, with segment forecasts adjusted for market and operational factors.
-
Core operating income rebounded sharply in H1 FY2024, led by IT-related Chemicals and Pharmaceuticals, despite a net loss from one-off factors. The company raised its cash generation target, advanced structural reforms, and maintained its dividend policy while focusing on growth in specialty and green materials.